Status:
TERMINATED
Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)
Lead Sponsor:
Sarepta Therapeutics, Inc.
Conditions:
Cardiovascular Disease
Coronary Artery Bypass
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
For some people who have heart by-pass surgery, the vein that is used to by-pass a blockage will, after some time, become narrowed and possibly blocked. AVI-5126 blocks a gene that is believed to be r...
Detailed Description
Coronary artery bypass (CABG) is a common procedure employed for life-threatening cardiovascular disease. While bypass surgery is effective in restoring blood flow in the short-term, 30 to 50 percent ...
Eligibility Criteria
Inclusion
- Subject is ≥ 18 years of age
- Subject is a suitable candidate for aortocoronary bypass (CABG) procedure. Subjects undergoing CABG procedure without the use of coronary artery bypass (off pump) are preferred. However, subjects requiring coronary artery bypass will not be excluded from the study
- Female subjects of childbearing potential must have a documented negative serum pregnancy test within 2 days before the CABG procedure
- Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
- Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.
Exclusion
- Subject will have valve replacement or repair during CABG procedure
- Subject has a poor quality donor vessel (poor or turbulent flow, varicose)
- Subject has a known left ventricular ejection fraction of \<35%
- Subject has had a percutaneous coronary intervention (PCI) for coronary artery disease treatment 30 days prior to CABG
- Subject has a PCI planned during the 30 days immediately following the CABG procedure
- Subject has chronic atrial fibrillation
- Subject has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, or sensitivity to contrast media which cannot be adequately pre-medicated
- Subject has chronic renal insufficiency (i.e., serum creatinine \>180 mmol/L) or co-morbid illness which precludes follow-up angiography
- Subject has history of a stroke or transient ischemic attack within the prior 6 months
- Subject has an active peptic ulcer or has had clinically significant upper or lower GI bleeding within the prior 6 months
- Subject has a history of a bleeding diathesis or coagulopathy or will refuse blood transfusions
- Subject has a non-cardiac illness imposing substantial operative mortality
- Subject has a concurrent medical condition resulting in a life expectancy of less than 3 years
- Subject is currently participating in an investigational drug or another device study.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00451256
Start Date
March 1 2007
End Date
March 1 2009
Last Update
July 8 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kiev, Ukraine